We held the 1st China Pharma IP Summit 2016 on 17-18, November 2016 and confirmed more than 190 attendees from government agencies, in-house IP counsel, IP law firms, agencies and solution providers. The development of pharmaceutical industry heavily relies on their IP strategies, and this year pharmaceutical IP protection in China is drawing more attentions than before. Firstly, on 12th May 2017, the China Food and Drug Administration issued a proposal ( called 2017 Policy Notice No.55), which proposes to establish the patent linkage and amend the regulatory data protection regime. In the Notice No.55, it indicates the procedures of patent linkage and changes of regulatory data protection. Secondly, China is studying the drug patent extension reform, and the result may come out within this year. Additionally, the SIPO is amending PATENT LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the new amendments to SIPO's Guidelines for Patent Examination has been effective since 1st April, 2017.

Based on the above, we will launch 2nd China Pharma IP Summit 2017 on 7th -8th December 2017 in Shanghai, and continue to provide a networking platform for industry peers. Through this event, you can:

1. Follow updated policies in China, including patent linkage, regulatory data protection, patent extension reform, and the changes of Patent Law and Guidelines for Patent Examination
2. Understand the latest examination standards and litigation proceedings in the U.S. and Europe
3. Learn excellent IP management cases
4. Meet your clients face to face and interact with industry peers

The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, and research institutes.